^
Association details:
| Biomarker: | AR overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | orteronel (TAK 700) (Androgen receptor antagonist, Lyase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple- negative breast cancer (TNBC)
Published date:
11/17/2020
Excerpt:
...orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC)...The ORR was 4% and DCR was 15%. Median PFS was 2.0 mo and median OS was 10.2 mo...Orteronel monotherapy was well tolerated but demonstrated limited clinical activity in this heavily pre-treated metastatic AR+ TNBC patient population.
